Freeline sets range for US IPO as biotech 'bananas' surge continues
Freeline Therapeutics, the UK gene therapeutics company, has set a pricing range for its Nasdaq listing, becoming the latest company from the red hot biotech sector to raise equity capital.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: